Molecular Cancer

Article	Citations
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives	965
Circular RNA: metabolism, functions and interactions with proteins	657
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions	561
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance	536
mRNA vaccine for cancer immunotherapy	532
The cancer metabolic reprogramming and immune response	522
Targeting TGF-β signal transduction for fibrosis and cancer therapy	385
Glioma targeted therapy: insight into future of molecular approaches	372
Exosomes as a new frontier of cancer liquid biopsy	368
Wnt signaling in colorectal cancer: pathogenic role and therapeutic target	330
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments	323
The role of m6A RNA methylation in cancer metabolism	303
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy	297
Exosome-based immunotherapy: a promising approach for cancer treatment	289
G-quadruplexes: a promising target for cancer therapy	286
The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities	283
Lung cancer immunotherapy: progress, pitfalls, and promises	280
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities	278
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer	278
Cuproptosis: mechanisms and links with cancers	234
Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments	229
mRNA vaccine: a potential therapeutic strategy	222
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc	221
mRNA therapeutics in cancer immunotherapy	208
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation	197

Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies	196
m6A modification: recent advances, anticancer targeted drug discovery and beyond	194
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer	193
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer	193
Long noncoding RNAs: functions and mechanisms in colon cancer	192
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer	189
Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine	184
N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling	184
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	183
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer	174
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer	168
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring	164
Cancer associated-fibroblast-derived exosomes in cancer progression	154
circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2	152
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer	151
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy	150
Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer	149
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing	147
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	147
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances	147
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy	133
The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation	132
A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling	132
Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC	128
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer	125
Advancements in nanoparticle-based treatment approaches for skin cancer therapy	120
Circular RNA hsa_circ_0004872 inhibits gastric cancer progression via the miR-224/Smad4/ADAR1 successive regulatory circuit	118
Proteolysis-targeting chimeras (PROTACs) in cancer therapy	118
Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis	117
Insights into N6-methyladenosine and programmed cell death in cancer	117
Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer	116
DDX3X: structure, physiologic functions and cancer	115
Circ3823 contributes to growth, metastasis and angiogenesis of colorectal cancer: involvement of miR-30c-5p/TCF7 axis	114
Targeting the RNA m6A modification for cancer immunotherapy	114
Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer	111
LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM	111
Targeting the tumor stroma for cancer therapy	108
Non-coding RNAs regulation of macrophage polarization in cancer	108
METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis	108
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer	107
Proteomics technologies for cancer liquid biopsies	102
circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway	102
M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma	102
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition	102
Comprehensive landscape and future perspectives of circular RNAs in colorectal cancer	102
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy	101
The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies	100
Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification	100
Clinical and immunological effects of mRNA vaccines in malignant diseases	99
Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development	99

Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin	99
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma	98
Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms	97
Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3–eIF3h interaction	97
Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development	96
A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study	95
Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma	95
Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression	92
Molecular mechanisms of tumor resistance to radiotherapy	92
CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression	91
Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential	91
The circular RNA circSPARC enhances the migration and proliferation of colorectal cancer by regulating the JAK/STAT pathway	90
Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer	90
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers	89
Targeting KRAS mutant cancers: from druggable therapy to drug resistance	87
CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1-529aa protein and regulating PRDX2 protein stability	87
CD39/CD73/A2AR pathway and cancer immunotherapy	86
Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications	86
Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy	84
LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer	84
Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?	84
Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma	83
The m6A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis	81
Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling	80
The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p	80
Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p	80
Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications	80
CircIL4R activates the PI3K/AKT signaling pathway via the miR-761/TRIM29/PHLPP1 axis and promotes proliferation and metastasis in colorectal cancer	80
The journey of CAR-T therapy in hematological malignancies	79
A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin signaling pathway to promote gastric cancer progression	78
The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin	77
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance	76
Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis	76
CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway	75
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma	75
A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma	75
CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma	74
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer	74
CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing	74
FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2	74
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials	73
ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma	73
Potential clinical utility of liquid biopsies in ovarian cancer	73
circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis	72
Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2	72
Delivery of cancer therapies by synthetic and bio-inspired nanovectors	72
LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway	72
Gold nanoparticles and gold nanorods in the landscape of cancer therapy	71
Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling	71
Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types	70
Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy	69
RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment	69
Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA	68
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers	68
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades	68
Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis	67
Histone citrullination: a new target for tumors	66
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer	66
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer	66
CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer	65
Targeting HNRNPU to overcome cisplatin resistance in bladder cancer	64
Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis	64
Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions	64
CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p	64
The functional roles of the circRNA/Wnt axis in cancer	64
The role and application of small extracellular vesicles in gastric cancer	63
A clinician’s handbook for using ctDNA throughout the patient journey	63
The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer	63
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer	62
The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells	61
Regulatory cells and the effect of cancer immunotherapy	61
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy	60
Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling	59
Clinical significance of FBXW7 loss of function in human cancers	59
CircMYH9 drives colorectal cancer growth by regulating serine metabolism and redox homeostasis in a p53-dependent manner	59
Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer	59
CircEZH2/miR-133b/IGF2BP2 aggravates colorectal cancer progression via enhancing the stability of m6A-modified CREB1 mRNA	59
circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF-β/Smad signaling	59
NK cells and solid tumors: therapeutic potential and persisting obstacles	59
A novel class of tsRNA signatures as biomarkers for diagnosis and prognosis of pancreatic cancer	58

CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes	57
Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses	57
Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma	56
RNA-based therapies: A cog in the wheel of lung cancer defense	56
Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion	56
The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC	56
CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer	55
Circular RNAs’ cap-independent translation protein and its roles in carcinomas	55
Small extrachromosomal circular DNA (eccDNA): major functions in evolution and cancer	55
CircDOCK1 promotes the tumorigenesis and cisplatin resistance of osteogenic sarcoma via the miR-339-3p/IGF1R axis	55
Nanomaterials in tumor immunotherapy: new strategies and challenges	55
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy	54
Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression	54
Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients	54
Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma	54
CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma	53
The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma	53
The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis	52
Expanding uncapped translation and emerging function of circular RNA in carcinomas and noncarcinomas	52
Clinical application and detection techniques of liquid biopsy in gastric cancer	52
Hypoxia-induced circWSB1 promotes breast cancer progression through destabilizing p53 by interacting with USP10	52
Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication	52
Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance	51
Tumor-suppressive circRHOBTB3 is excreted out of cells via exosome to sustain colorectal cancer cell fitness	51
Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy	51
Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers	51
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment	51
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development	51
mRNA in cancer immunotherapy: beyond a source of antigen	51
SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions	50
N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma	50
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy	50
Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis	50
Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1	50
Nonsense-mediated RNA decay and its bipolar function in cancer	49
A novel NF-κB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation	48
A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR	47
Using single-cell sequencing technology to detect circulating tumor cells in solid tumors	47
Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer	46
RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics	46
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges	45
Clinical considerations for the design of PROTACs in cancer	45
The intersection of COVID-19 and cancer: signaling pathways and treatment implications	45
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial	44
The role of m6A methylation in therapy resistance in cancer	44
Advances in immunotherapy for triple-negative breast cancer	44
A urine extracellular vesicle circRNA classifier for detection of high-grade prostate cancer in patients with prostate-specific antigen 2–10 ng/mL at initial biopsy	44
CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2	44
AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR/p38 signaling pathway	44
Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis	44
Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma	44
The m6A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway	43
The use of RNA-based treatments in the field of cancer immunotherapy	43
CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein	43
CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling	42
Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis	42
CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity	42
Characterization of distinct circular RNA signatures in solid tumors	42
Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1	42
The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis	42
Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis	41
CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment	41
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma	41
CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma	41
NK cells are never alone: crosstalk and communication in tumour microenvironments	41
Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer	41
Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling	41
Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop	41
Biological and pharmacological roles of m6A modifications in cancer drug resistance	40
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials	40
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways	40
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T	40
KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1	40
CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer	40
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment	39
Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QBP ubiquitin degradation and mediating beta-catenin activation	39
p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation	39
circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer	38
Crosstalk between autophagy and microbiota in cancer progression	38
Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment	38
A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study	38
MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer	38
Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer	38
Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway	38
Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma	38
Circular RNA EIF4G3 suppresses gastric cancer progression through inhibition of β-catenin by promoting δ-catenin ubiquitin degradation and upregulating SIK1	38
Emerging roles of tRNA-derived fragments in cancer	37
Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade	37
Epigenetic modification of m6A regulator proteins in cancer	37
Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma	36
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy	36
The N6-methyladenosine modification of circALG1 promotes the metastasis of colorectal cancer mediated by the miR-342-5p/PGF signalling pathway	36
TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma	36
m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion	36
Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine	35